1
|
Hegedűs N, Forgách L, Kiss B, Varga Z, Jezsó B, Horváth I, Kovács N, Hajdrik P, Padmanabhan P, Gulyás B, Szigeti K, Máthé D. Correction: Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA). PLoS One 2023; 18:e0295460. [PMID: 38033129 PMCID: PMC10688837 DOI: 10.1371/journal.pone.0295460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2023] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0264554.].
Collapse
|
2
|
Szöllősi D, Hajdrik P, Tordai H, Horváth I, Veres DS, Gillich B, Shailaja KD, Smeller L, Bergmann R, Bachmann M, Mihály J, Gaál A, Jezsó B, Barátki B, Kövesdi D, Bősze S, Szabó I, Felföldi T, Oszwald E, Padmanabhan P, Gulyás BZ, Hamdani N, Máthé D, Varga Z, Szigeti K. Molecular imaging of bacterial outer membrane vesicles based on bacterial surface display. Sci Rep 2023; 13:18752. [PMID: 37907509 PMCID: PMC10618197 DOI: 10.1038/s41598-023-45628-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 10/21/2023] [Indexed: 11/02/2023] Open
Abstract
The important roles of bacterial outer membrane vesicles (OMVs) in various diseases and their emergence as a promising platform for vaccine development and targeted drug delivery necessitates the development of imaging techniques suitable for quantifying their biodistribution with high precision. To address this requirement, we aimed to develop an OMV specific radiolabeling technique for positron emission tomography (PET). A novel bacterial strain (E. coli BL21(DE3) ΔnlpI, ΔlpxM) was created for efficient OMV production, and OMVs were characterized using various methods. SpyCatcher was anchored to the OMV outer membrane using autotransporter-based surface display systems. Synthetic SpyTag-NODAGA conjugates were tested for OMV surface binding and 64Cu labeling efficiency. The final labeling protocol shows a radiochemical purity of 100% with a ~ 29% radiolabeling efficiency and excellent serum stability. The in vivo biodistribution of OMVs labeled with 64Cu was determined in mice using PET/MRI imaging which revealed that the biodistribution of radiolabeled OMVs in mice is characteristic of previously reported data with the highest organ uptakes corresponding to the liver and spleen 3, 6, and 12 h following intravenous administration. This novel method can serve as a basis for a general OMV radiolabeling scheme and could be used in vaccine- and drug-carrier development based on bioengineered OMVs.
Collapse
Affiliation(s)
- Dávid Szöllősi
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Polett Hajdrik
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Hedvig Tordai
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Ildikó Horváth
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Dániel S Veres
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Bernadett Gillich
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Kanni Das Shailaja
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - László Smeller
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Ralf Bergmann
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
- Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 400 Bautzner Landstraße, 01328, Dresden, Germany
| | - Michael Bachmann
- Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 400 Bautzner Landstraße, 01328, Dresden, Germany
| | - Judith Mihály
- Biological Nanochemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, 2 Magyar Tudósok Körútja, Budapest, 1117, Hungary
| | - Anikó Gaál
- Biological Nanochemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, 2 Magyar Tudósok Körútja, Budapest, 1117, Hungary
| | - Bálint Jezsó
- Biological Nanochemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, 2 Magyar Tudósok Körútja, Budapest, 1117, Hungary
- Doctoral School of Biology and Institute of Biology, Eötvös Loránd University, 1/C Pázmány Péter Sétány, Budapest, 1117, Hungary
| | - Balázs Barátki
- Department of Immunology, ELTE Eötvös Loránd University, 1/C Pázmány Péter Sétány, Budapest, 1117, Hungary
| | - Dorottya Kövesdi
- Department of Immunology, ELTE Eötvös Loránd University, 1/C Pázmány Péter Sétány, Budapest, 1117, Hungary
- MTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), 1/A Pázmány Péter Sétány, Budapest, 1117, Hungary
| | - Szilvia Bősze
- ELKH-ELTE Research Group of Peptide Chemistry, Eötvös L. Research Network, Eötvös L. University, 1/A Pázmány Péter Sétány, Budapest, 1117, Hungary
| | - Ildikó Szabó
- ELKH-ELTE Research Group of Peptide Chemistry, Eötvös L. Research Network, Eötvös L. University, 1/A Pázmány Péter Sétány, Budapest, 1117, Hungary
| | - Tamás Felföldi
- Department of Microbiology, ELTE Eötvös Loránd University, 1/C Pázmány Péter Sétány, Budapest, 1117, Hungary
- Centre for Ecological Research, Institute of Aquatic Ecology, 29 Karolina Road, Budapest, 1113, Hungary
| | - Erzsébet Oszwald
- Department of Anatomy, Histology, and Embryology, Semmelweis University, 58 Tűzoltó Street, Budapest, 1094, Hungary
| | - Parasuraman Padmanabhan
- Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Singapore, 30823, Singapore
- Cognitive Neuroimaging Centre, Nanyang Technological University, 59 Nanyang Drive, Singapore, 636921, Singapore
| | - Balázs Zoltán Gulyás
- Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Singapore, 30823, Singapore
- Cognitive Neuroimaging Centre, Nanyang Technological University, 59 Nanyang Drive, Singapore, 636921, Singapore
| | - Nazha Hamdani
- Department of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, 44801, Bochum, Germany
- HCEMM-Cardiovascular Research Group, Department of Pharmacology and Pharmacotherapy, University of Budapest, Budapest, 1089, Hungary
| | - Domokos Máthé
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
- CROmed Translational Research Centers, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
- In Vivo Imaging Advanced Core Facility, Hungarian Center of Excellence for Molecular Medicine (HCEMM), 37-47 Tűzoltó Street, Budapest, 1094, Hungary
| | - Zoltán Varga
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary
- Biological Nanochemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, 2 Magyar Tudósok Körútja, Budapest, 1117, Hungary
| | - Krisztián Szigeti
- Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó Street, Budapest, 1094, Hungary.
| |
Collapse
|
3
|
Kegler A, Drewitz L, Arndt C, Daglar C, Rodrigues Loureiro L, Mitwasi N, Neuber C, González Soto KE, Bartsch T, Baraban L, Ziehr H, Heine M, Nieter A, Moreira-Soto A, Kühne A, Drexler JF, Seliger B, Laube M, Máthé D, Pályi B, Hajdrik P, Forgách L, Kis Z, Szigeti K, Bergmann R, Feldmann A, Bachmann M. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells. Front Immunol 2023; 14:1204543. [PMID: 37383226 PMCID: PMC10293748 DOI: 10.3389/fimmu.2023.1204543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 05/17/2023] [Indexed: 06/30/2023] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2 in vitro and in SARS-CoV-2-infected animal models but also for (ii) clearance of virus-infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule, which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor-modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.
Collapse
Affiliation(s)
- Alexandra Kegler
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Laura Drewitz
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Claudia Arndt
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Cansu Daglar
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Liliana Rodrigues Loureiro
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Nicola Mitwasi
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Christin Neuber
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Karla Elizabeth González Soto
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Tabea Bartsch
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Larysa Baraban
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Holger Ziehr
- Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany
| | - Markus Heine
- Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany
| | - Annabel Nieter
- Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany
| | - Andres Moreira-Soto
- Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Arne Kühne
- Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Jan Felix Drexler
- Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Barbara Seliger
- Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany
- Institute of Translational Immunology, Medical High School, Brandenburg an der Havel, Germany
| | - Markus Laube
- Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Domokos Máthé
- Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
- Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, Szeged, Hungary
- CROmed Translational Research Ltd., Budapest, Hungary
| | - Bernadett Pályi
- National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary
| | - Polett Hajdrik
- Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
| | - László Forgách
- Semmelweis University School of Pharmacy, Semmelweis University, Budapest, Hungary
| | - Zoltán Kis
- National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary
| | - Krisztián Szigeti
- Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
| | - Ralf Bergmann
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
| | - Anja Feldmann
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- National Center for Tumor Diseases Dresden (NCT), German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Bachmann
- Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- National Center for Tumor Diseases Dresden (NCT), German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
4
|
Hegedűs N, Forgách L, Kiss B, Varga Z, Jezsó B, Horváth I, Kovács N, Hajdrik P, Padmanabhan P, Gulyás B, Szigeti K, Máthé D. Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA). PLoS One 2022; 17:e0264554. [PMID: 35857783 PMCID: PMC9299340 DOI: 10.1371/journal.pone.0264554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 02/12/2022] [Indexed: 11/21/2022] Open
Abstract
The aim of this study was to develop and characterize a Prussian Blue based biocompatible and chemically stable T1 magnetic resonance imaging (MRI) contrast agent with near infrared (NIR) optical contrast for preclinical application. The physical properties of the Prussian blue nanoparticles (PBNPs) (iron (II); iron (III);octadecacyanide) were characterized with dynamic light scattering (DLS), zeta potential measurement, atomic force microscopy (AFM), and transmission electron microscopy (TEM). In vitro contrast enhancement properties of PBNPs were determined by MRI. In vivo T1-weighted contrast of the prepared PBNPs was investigated by MRI and optical imaging modality after intravenous administration into NMRI-Foxn1 nu/nu mice. The biodistribution studies showed the presence of PBNPs predominantly in the cardiovascular system. Briefly, in this paper we show a novel approach for the synthesis of PBNPs with enhanced iron content for T1 MRI contrast. This newly synthetized PBNP platform could lead to a new diagnostic agent, replacing the currently used Gadolinium based substances.
Collapse
Affiliation(s)
- Nikolett Hegedűs
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - László Forgách
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Bálint Kiss
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Zoltán Varga
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
- Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Science, Budapest, Hungary
| | - Bálint Jezsó
- Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Science, Budapest, Hungary
| | - Ildikó Horváth
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Noémi Kovács
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Polett Hajdrik
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Parasuraman Padmanabhan
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
- Cognitive Neuroimaging Centre, Nanyang Technological University, Singapore, Singapore
| | - Balázs Gulyás
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
- Cognitive Neuroimaging Centre, Nanyang Technological University, Singapore, Singapore
- Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
| | - Krisztián Szigeti
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Domokos Máthé
- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
- CROmed Translational Research Centers, Budapest, Hungary
- In Vivo Imaging Advanced Core Facility, Hungarian Center of Excellence for Molecular Medicine (HCEMM), Budapest, Hungary
| |
Collapse
|
5
|
Hajdrik P, Pályi B, Kis Z, Kovács N, Veres DS, Szigeti K, Budán F, Hegedüs I, Kovács T, Bergmann R, Máthé D. In Vitro Determination of Inhibitory Effects of Humic Substances Complexing Zn and Se on SARS-CoV-2 Virus Replication. Foods 2022; 11:694. [PMID: 35267328 PMCID: PMC8909382 DOI: 10.3390/foods11050694] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/22/2022] [Accepted: 02/23/2022] [Indexed: 02/06/2023] Open
Abstract
(1) Background: Humic substances are well-known human nutritional supplement materials and they play an important performance-enhancing role as animal feed additives. For decades, ingredients of humic substances have been proven to carry potent antiviral effects against different viruses. (2) Methods: Here, the antiviral activity of a humic substance containing ascorbic acid, Se- and Zn2+ ions intended as a nutritional supplement material was investigated against SARS-CoV-2 virus B1.1.7 Variant of Concern ("Alpha Variant") in a VeroE6 cell line. (3) Results: This combination has a significant in vitro antiviral effect at a very low concentration range of its intended active ingredients. (4) Conclusions: Even picomolar concentration ranges of humic substances, Vitamin C and Zn/Se ions in the given composition, were enough to achieve 50% viral replication inhibition in the applied SARS-CoV-2 virus inhibition test.
Collapse
Affiliation(s)
- Polett Hajdrik
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
| | - Bernadett Pályi
- National Biosafety Laboratory, National Public Health Center, Albert Flórián út 2-6, H-1097 Budapest, Hungary; (B.P.); (Z.K.)
| | - Zoltán Kis
- National Biosafety Laboratory, National Public Health Center, Albert Flórián út 2-6, H-1097 Budapest, Hungary; (B.P.); (Z.K.)
- Department of Microbiology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary
| | - Noémi Kovács
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
- CROmed Translational Research Ltd., Tűzoltó u. 37-47, H-1094 Budapest, Hungary
| | - Dániel Sándor Veres
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
| | - Krisztián Szigeti
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
| | - Ferenc Budán
- Institute of Transdisciplinary Discoveries, Medical School, University of Pécs, Ifjúság útja 11, H-7624 Pécs, Hungary;
- Institute of Physiology, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary
| | - Imre Hegedüs
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
| | - Tibor Kovács
- Institute of Radiochemistry and Radioecology, University of Pannonia, Egyetem u. 10., H-8200 Veszprem, Hungary;
| | - Ralf Bergmann
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
- Helmholtz-Zentrum Dresden Rossendorf, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Domokos Máthé
- Department of Biophysics and Radiation Biology, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.H.); (N.K.); (D.S.V.); (K.S.); (I.H.); (R.B.)
- CROmed Translational Research Ltd., Tűzoltó u. 37-47, H-1094 Budapest, Hungary
- Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, Semmelweis University Site, Római Blvd. 21, H-6723 Szeged, Hungary
| |
Collapse
|